Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia

by José R. González-Porras, Bertrand Godeau, Monica Carpenedo
Published 2019-03-01

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

by Maria L. Lozano, Cristina Segú-Vergés, Mireia Coma, María T. Álvarez-Roman, José R. González-Porras, Laura Gutiérrez, David Valcárcel, Nora Butta
Published 2021-06-01

Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

by Maria L. Lozano, Maria E. Mingot-Castellano, María M. Perera, Isidro Jarque, Rosa M. Campos-Alvarez, Tomás J. González-López, Gonzalo Carreño-Tarragona, Nuria Bermejo, Maria F. Lopez-Fernandez, Aurora de Andrés, David Valcarcel, Luis F. Casado-Montero, Maria T. Alvarez-Roman, María I. Orts, Silvana Novelli, Nuria Revilla, Jose R. González-Porras, Estefanía Bolaños, Manuel A. Rodríguez-López, Elisa Orna-Montero, Vicente Vicente
Published 2021-08-01